Clinical Trial Results
Preclinical and Clinical results of ALPHA-1062
Alpha Cognition, Inc has performed multiple successful human clinical trials in adult and elderly subjects. These trials showed a statistically significant improvement in cognition measurements within seven days of treatment. We also observed a 95% reduction of severe side effects using intranasal ALPHA-1062 when compared to an oral dose of the currently approved cholinesterase inhibitor; galantamine.
Alpha-1062’s clinical success has led to the acceleration of our development program. We are now targeting submissions to the United States Food and Drug Administration (US FDA), European Medicinal Authority (EMA) and Japanese Pharmaceutical and Medical Devices Agency (PMDA) with the hope of having Alpha-1062 available globally for those who need it.